Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 9, Issue -, Pages 17-22Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2016.05.008
Keywords
Serum uric acid; Multiple sclerosis; Neuromyelitis optica; Patients; Updated; Meta-analysis
Categories
Ask authors/readers for more resources
Objectives: To evaluate the association between serum uric acid (UA) levels and patients with MS and NMO. Methods: The PubMed, Web of Science and Cochrane Library database were searched for relevant studies. Pooled standardized mean difference (SMD) and 95% confidence interval (CI) were used as effect size. Subgroup analysis was performed by gender, country, disease durations, scores of EDSS, detection method and clinical classification. Results: A total of 10 case-control studies involving 1537 patients (1308 MS patients, 229 NMO patients) and 908 healthy controls were included. We found the serum UA levels of patients with MS and NMO were significantly lower compared to those of healthy controls (SMD = - 0.52, 95%Cl, - 0.81 to - 0.24). In the subgroup analysis, there was no significant difference between serum UA levels in patients and healthy controls in European subgroup (SMD = - 0.32, 95%CI, - 0.78 to 0.14). Additionally, we found that serum UA levels were higher in MS and NMO patients than in healthy controls in EDSS > 3.5 subgroup (SMD = - 0.38, 95%CI, - 0.58 to - 0.19), but not in EDSS <= 3.5 subgroup (SMD = - 0.35, - 95%0, - 0.97 to 0.27). Patients of relapsing group had significant lower serum UA levels than patients of remitting group (SMD = 0.70, 95%Cl, 0.19-1.21). Conclusion: Patients with MS and NMO showed lower serum UA levels when compared with healthy controls. Serum UA might be a potential diagnostic biomarker for MS and NMO. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available